Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Down 69.9% in July

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 27,481 shares, a drop of 69.9% from the June 30th total of 91,267 shares. Based on an average daily volume of 29,455 shares, the short-interest ratio is currently 0.9 days. Approximately 0.8% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors and hedge funds own 11.84% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix currently has a consensus rating of “Sell”.

Pulmatrix Trading Down 6.8%

PULM opened at $1.65 on Friday. The stock has a market capitalization of $6.02 million, a PE ratio of -1.34 and a beta of 1.90. Pulmatrix has a 1-year low of $1.16 and a 1-year high of $5.80. The firm has a 50-day moving average price of $1.52 and a two-hundred day moving average price of $1.84.

Pulmatrix (NASDAQ:PULM) last announced its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).